945244-45-1 Usage
Uses
Used in Pharmaceutical Applications:
1-(6-fluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxylic acid is used as a potential pharmaceutical agent for various applications due to its complex molecular structure and the presence of a cyclopropane ring, which is found in many biologically active molecules. The fluorine atom in the benzodioxole group may also provide unique pharmacological properties, enhancing the compound's effectiveness in treating specific conditions or diseases.
Used in Drug Development Research:
In the field of drug development, 1-(6-fluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxylic acid is used as a starting material or a structural component in the synthesis of new drugs. Its unique molecular features make it a valuable candidate for further investigation and development, potentially leading to the creation of novel therapeutic agents.
Note: As the specific applications and industries for 1-(6-fluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxylic acid are not provided in the materials, the uses listed above are general and based on the compound's structural features and potential in pharmaceutical applications. Further research and investigation are required to determine its specific applications and industries.
Check Digit Verification of cas no
The CAS Registry Mumber 945244-45-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,5,2,4 and 4 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 945244-45:
(8*9)+(7*4)+(6*5)+(5*2)+(4*4)+(3*4)+(2*4)+(1*5)=181
181 % 10 = 1
So 945244-45-1 is a valid CAS Registry Number.
945244-45-1Relevant academic research and scientific papers
Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
-
, (2015/09/22)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
-
, (2012/04/23)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
Modulators of ATP-binding cassette transporters
-
Page/Page column 85, (2008/06/13)
Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
